Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Inclusion Criteria: * Patients with documented stage III NSCLC (IIIA or IIIB, without malignant pleural/pericardial effusion) are eligible for enrollment if they are considered appropriate for treatment with chemotherapy, radiation, or surgery; * IIIA: T1-3 N2 M0, T3 N1 M0 * IIIB: T4 N0-2 M0, T 1-4 N3 M0 * Measurable or evaluable disease * Previously untreated with chemotherapy or radiotherapy for lung cancer; * No brain metastases; * No prior XRT * Performance status 0-2 * ≥18 years of age * Informed Consent * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L * Platelets ≥ 100 x 109/L * Bilirubin ≤ 1.5 x upper limit of normal for the institution (ULN) * SGOT and SGPT ≤ 2.5 x ULN for the institution * Creatinine ≤ 1.6 mg/dL * Hemoglobin ≥ 8.0 g/dL * Peripheral neuropathy ≤ grade 1 Exclusion Criteria: * Known sensitivity to E. coli derived products (e.g. Filgrastim, HUMULIN® insulin, L-asparaginase, HUMATROPE® Growth Hormone, INTRON® A); * Use of IV systemic antibiotics within 72 hours prior to chemotherapy; * Known HIV infection * Lithium or cytokines within 2 weeks prior of entry * Additional concurrent investigational drugs * History of myelodysplastic syndrome * Pregnant, nursing or having unprotected sex * Not available for follow-up assessment * Unable to comply with protocol procedures * Illnesses that may compromise ability to give informed consent. * Patients with a history of severe hypersensitivity reaction to Taxotere® or other drugs formulated with polysorbate 80.